COMPASS Pathways plc (CMPS) stock
CMPSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.12−0.18 (-1.94%)
Close on Nov 12, 2026Market cap $1.26BP/E –Yield –
COMPASS Pathways ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
COMPASS Pathways's ebitda for the twelve months ending Sep 30, 2024 was -$168.12M. For fiscal 2023 it was -$136.68M. The highest annual figure on record is -$21.12M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$136.68M | – |
| FY2022 | Dec 31, 2022 | -$110.07M | – |
| FY2021 | Dec 31, 2021 | -$83.05M | – |
| FY2020 | Dec 31, 2020 | -$51.28M | – |
| FY2019 | Dec 31, 2019 | -$21.12M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -$47.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$43.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$38.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.59M | – |
See a number that looks wrong?